Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Autor: Eberlein CA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Stetson D; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Markovets AA; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Al-Kadhimi KJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Lai Z; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Fisher PR; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., Meador CB; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Spitzler P; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Ichihara E; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Ross SJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Ahdesmaki MJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Ahmed A; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Ratcliffe LE; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., O'Brien EL; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom., Barnes CH; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Brown H; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Smith PD; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Dry JR; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Beran G; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom., Thress KS; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Dougherty B; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts., Pao W; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Cross DA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom. Darren.Cross@astrazeneca.com.

Publikováno v: Cancer research [Cancer Res] 2015 Jun 15; Vol. 75 (12), pp. 2489-500. Date of Electronic Publication: 2015 Apr 13.